• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Hamilton Lane Incorporated filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    2/12/25 4:21:19 PM ET
    $HLNE
    Investment Managers
    Finance
    Get the next $HLNE alert in real time by email
    hlne-20250210
    0001433642false00014336422025-02-102025-02-10


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): February 10, 2025
    Hamilton Lane Incorporated
    (Exact Name of Registrant as specified in its charter)
    Delaware001-3802126-2482738
    (State or other jurisdiction of incorporation)
    (Commission File No.)(IRS Employer Identification No.)
    110 Washington Street,Suite 1300
    Conshohocken, PA19428
    (Address of principal executive offices)
    (Zip Code)
     (610) 934-2222 
    (Registrant’s telephone number, including area code)
    Not Applicable
    (Former Name or Former Address, if Changed Since Last Report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐
     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Class A Common Stock, $0.001 par value per shareHLNEThe Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐



    Item 8.01. Other Events.

    On February 10, 2025, Hamilton Lane Incorporated (the “Company”), Hamilton Lane Advisors, L.L.C. (“HLA”) and a selling stockholder entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC (the “Underwriter”) relating to the sale of 1,572,536 shares of Class A common stock, par value $0.001 per share (“Class A Common Stock”), of the Company at a price to the Underwriter of $159.00 per share in a registered public offering (the “Offering”). The Offering closed on February 12, 2025. The Company issued and sold 1,562,281 shares of Class A Common Stock, and the selling stockholder sold 10,255 shares of Class A Common Stock in the Offering. The Offering generated net proceeds for the Company of $248.4 million and net proceeds for the selling stockholder of $1.6 million. The Company intends to use the proceeds to settle in cash exchanges of membership units in HLA held by certain of its members. The Company did not receive any proceeds from the sale of shares by the selling stockholder.

    The Underwriting Agreement contains customary representations and warranties of the parties, and indemnification and contribution provisions under which the Company, HLA and the selling stockholder have agreed to indemnify the Underwriter against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Pursuant to the Underwriting Agreement, the Company has agreed, subject to certain exceptions, not to sell or transfer any shares of Class A Common Stock or any securities convertible into or exercisable or exchangeable for Class A Common Stock for 45 days after February 10, 2025 without first obtaining the written consent of the Underwriter. The foregoing description is a summary and is qualified in its entirety by reference to the complete text of the Underwriting Agreement filed as Exhibit 1.1 hereto and incorporated herein by reference.

    The Offering was made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the “SEC”) on November 14, 2024 (File No. 333-283233), a base prospectus included as part of the registration statement, and a prospectus supplement, dated February 10, 2025, filed with the SEC pursuant to Rule 424(b) under the Securities Act. The Company is filing as Exhibit 5.1 to this Current Report on Form 8-K an opinion of its counsel, Faegre Drinker Biddle & Reath LLP, regarding certain Delaware law issues concerning the shares of Class A Common Stock sold in the Offering.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits
    Exhibit No.Description
    1.1
    Underwriting Agreement, dated February 10, 2025, among the Company, HLA, Morgan Stanley & Co. LLC and the selling stockholder referenced therein
    5.1
    Opinion of Faegre Drinker Biddle & Reath LLP, dated February 12, 2025
    23.1
    Consent of Faegre Drinker Biddle & Reath LLP (contained in Exhibit 5.1 above)
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)




    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    HAMILTON LANE INCORPORATED
    Date: February 12, 2025
    By: /s/ Lydia A. Gavalis
    Name:Lydia A. Gavalis
    Title:General Counsel and Secretary


    Get the next $HLNE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HLNE

    DatePrice TargetRatingAnalyst
    5/15/2025Outperform → Perform
    Oppenheimer
    1/21/2025$186.00Perform → Outperform
    Oppenheimer
    1/6/2025$139.00Neutral → Sell
    Goldman
    9/12/2024$156.00Equal Weight
    Wells Fargo
    4/11/2024$115.00Overweight → Neutral
    JP Morgan
    1/11/2024Outperform → Perform
    Oppenheimer
    5/26/2023$87.00Perform → Outperform
    Oppenheimer
    3/15/2023$85.00Neutral → Overweight
    JP Morgan
    More analyst ratings